Genomic Biomarkers Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 9.20 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Genomic Biomarkers Market Analysis
The global genomic biomarkers market is expected to witness a CAGR of 9.2% over the forecast period. The rising burden of chronic diseases (cardiovascular diseases, cancer, strokes, and arthritis), high demand for minimally invasive procedures, technological advancements, development in R&D, and the infrastructure for data sharing and the demand for personalized medicines are expected to drive the growth during the forecast period. Technologies such as Gene Expression Profiling (microarray) and Next-Generation Sequencing (NGS) are currently the leading advances in this market segment. According to the World Health Organization's estimation in 2018, nearly 1 out of every 6 death is due to cancer followed by cardiovascular diseases, which accounts for the number one cause of death in the world. In August 2020, GeneCentric Therapeutic announced its entry into a research collaboration with Janssen Research & Development, LLC around an RNA-Based genomic biomarker, to develop novel non- invasive bladder cancer (NMIBC). According to a 2015 publication by the United States Food and Drug Administration (USFDA), they have undertaken several initiatives to initiate the use of genomic biomarkers in the development of medicinal products. However, high cost, complex development process, stringent government regulations and lack of standardized means to validate the marker may impose few challenges in the growth of genomic biomarkers market.
Genomic Biomarkers Market Trends
This section covers the major market trends shaping the Genomic Biomarkers Market according to our research experts:
Oncology Segment is Expected to Dominate the Market in The Forecast Period
Based on the indication, the oncology segment is expected to lead the market growth. Oncology biomarkers are expected to show significant growth due to an increase in the prevalence of various types of cancers such as breast, prostate, and lung cancer. In addition, push-in target therapies, technological advancements, and reliability on oncology biomarkers drive the growth of the market. As per the 2018 estimation by the International Agency for Research on Cancer (IRAC), the global burden is expected to reach 27.5 million new cancer cases by 2040. The factors responsible for the growing burden include smoking, unhealthy lifestyle, and lack of physical activities. The burden may probably further increase beyond IRAC estimation, thus increasing the opportunities in terms of the patient pool and customized medicines. Further, such factors escalating, the biopharmaceutical companies are expected to have higher priorities in relation to the expansion of products under the oncology category, thus, expected to boost the growth of this market, over the forecast period.
North America is Expected to Lead the Market
In terms of geography, North America is expected to hold the highest market share in the forecast period. The major reasons accelerating the market in this region includes developed healthcare infrastructure, favorable government policies, and huge research grants. The United States is by far leading the market in North America and continues to do so even in the forecast period. For instance, in August 2020 Cancer Genetics Inc., a US-based company signed a definitive merger agreement with StemoniX, a private company to accelerate the development of preclinical and clinical pipelines for biopharma partners as well as for the proprietary pipeline of the combined company. Such engagements in extensive R&D activities, advanced technologies, and substantial funding by the government as well as by the private organizations project the array of growth in the United States. Similar trends can be expected over the forecast period.
Genomic Biomarkers Industry Overview
The Genomic Biomarkers Market is highly competitive owing to the presence of large number of competitors. To sustain and increase footprints in such a competitive landscape, major players are adopting a lot of strategies such as product innovations, expansions, technology upgrades, investments in R&D as well as mergers and acquisitions. In 2018, BioMrieux SA completed the acquisition of Astute Medical to have access to biomarkers in the product pipeline of Astute Medical.
Major players currently in the market include Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Myriad Genetics Inc, Eurofins Scientific, QIAGEN etc.
Genomic Biomarkers Market Leaders
-
Thermo Fisher Scientific Inc.
-
F. Hoffmann-La Roche Ltd
-
Myriad Genetics Inc
-
Eurofins Scientific
-
QIAGEN
*Disclaimer: Major Players sorted in no particular order
Genomic Biomarkers Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Increasing Prevelance of Chronic Diseases
- 4.2.2 Technological Adancements in Molecular Biology, Genetics, Omics Technologies and Bioinformatics
- 4.2.3 Growing Awareness about Genomics Biomarkers
-
4.3 Market Restraints
- 4.3.1 Lack of Standardized Means for Validating the Marker
- 4.3.2 Stringent Government Regulations
-
4.4 Porter's Five Force Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
-
5.1 By Indication
- 5.1.1 Oncology
- 5.1.2 Cardiovascular diseases
- 5.1.3 Neurological diseases
- 5.1.4 Renal Disorders
- 5.1.5 Others
-
5.2 By End User
- 5.2.1 Hospitals
- 5.2.2 Diagnostic Centers
- 5.2.3 Others
-
5.3 Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Mexico
- 5.3.2 Europe
- 5.3.2.1 Germany
- 5.3.2.2 United Kingdom
- 5.3.2.3 France
- 5.3.2.4 Italy
- 5.3.2.5 Spain
- 5.3.2.6 Rest of Europe
- 5.3.3 Asia-Pacific
- 5.3.3.1 China
- 5.3.3.2 Japan
- 5.3.3.3 India
- 5.3.3.4 Australia
- 5.3.3.5 South Korea
- 5.3.3.6 Rest of Asia-Pacific
- 5.3.4 Middle-East and Africa
- 5.3.4.1 GCC
- 5.3.4.2 South Africa
- 5.3.4.3 Rest of Middle East and Africa
- 5.3.5 South America
- 5.3.5.1 Brazil
- 5.3.5.2 Argentina
- 5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Almac Group
- 6.1.2 Bio-Rad Laboratories Inc.
- 6.1.3 Cancer Genetics Inc
- 6.1.4 Eurofins Scientific
- 6.1.5 F. Hoffmann-La Roche Ltd
- 6.1.6 Genomic Health
- 6.1.7 Myriad Genetics Inc
- 6.1.8 QIAGEN
- 6.1.9 Thermo Fisher Scientific Inc
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityGenomic Biomarkers Industry Segmentation
Genomic biomarkers are Deoxyribonucleic acid (DNA) and Ribonucleic acid (RNA) characteristics, that are used as an indicator of diagnosis, disease characterization, and therapy selection. It reflects biological and pathogenic processes and response to therapeutic or other intervention. They are variant in the DNA code that alone or in combination enables early detection of disease by predicting its risk and improves patient treatment by monitoring the outcomes.
| By Indication | Oncology | |
| Cardiovascular diseases | ||
| Neurological diseases | ||
| Renal Disorders | ||
| Others | ||
| By End User | Hospitals | |
| Diagnostic Centers | ||
| Others | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle-East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Genomic Biomarkers Market Research FAQs
What is the current Genomic Biomarkers Market size?
The Genomic Biomarkers Market is projected to register a CAGR of 9.20% during the forecast period (2024-2029)
Who are the key players in Genomic Biomarkers Market?
Thermo Fisher Scientific Inc. , F. Hoffmann-La Roche Ltd , Myriad Genetics Inc, Eurofins Scientific and QIAGEN are the major companies operating in the Genomic Biomarkers Market.
Which is the fastest growing region in Genomic Biomarkers Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Genomic Biomarkers Market?
In 2024, the North America accounts for the largest market share in Genomic Biomarkers Market.
What years does this Genomic Biomarkers Market cover?
The report covers the Genomic Biomarkers Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Genomic Biomarkers Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Genomic Biomarkers Industry Report
Statistics for the 2024 Genomic Biomarkers market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Genomic Biomarkers analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
